Expired activity
Please go to the PowerPak homepage and select a course.

Emerging Treatment Options for RET-Driven Non-Small Cell Lung and Thyroid Cancers: Preparing Pharmacists to Optimize Patient Care (Recorded Podcast)

References »

FACULTY

R. Donald Harvey III, PharmD, BCOP, FCCP, FHOPA
Professor, Department of Hematology and Medical Oncology and
Department of Pharmacology and Chemical Biology
Emory University School of Medicine
Director, Phase l Clinical Trials Section
Atlanta, GA

At the conclusion of the activities the learner will be able to:

  • Discuss the RET pathway and its implication in NSCLC and thyroid cancer
  • Describe the evolution of therapies targeting RET

Back to Top